Halozyme Therapeutics
HALO
$33.88
Share price
-0.82%
Change (1 day)
-26.67%
Change (1 year)
Categories
Halozyme Therapeutics (HALO) - P/B ratio
P/B ratio as of June 2023 : 26.5
According to Halozyme Therapeutics's latest financial reports the company has a price-to-book ratio of 26.5.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Halozyme Therapeutics - P/B ratio (from 2004 to 2022)
P/B ratio by year
| Year | P/B ratio | Change |
|---|---|---|
| 2022-12-31 | 45.3 | 57.64% |
| 2021-12-31 | 28.7 | -24.8% |
| 2020-12-31 | 38.2 | 44.71% |
| 2019-12-31 | 26.4 | 210.5% |
| 2018-12-31 | 8.51 | -38.54% |
| 2017-12-31 | 13.8 | -135.14% |
| 2016-12-31 | -39.4 | -176.26% |
| 2015-12-31 | 51.6 | 76.05% |
| 2014-12-31 | 29.3 | -134.16% |
| 2013-12-31 | -85.9 | -654.78% |
| 2012-12-31 | 15.5 | -82.89% |
| 2011-12-31 | 90.5 | 131.13% |
| 2010-12-31 | 39.1 | -49.79% |
| 2009-12-31 | 78.0 | 162.89% |
| 2008-12-31 | 29.7 | 209.28% |
| 2007-12-31 | 9.59 | -60% |
| 2006-12-31 | 24.0 | 298.07% |
| 2005-12-31 | 6.02 | -17.52% |
| 2004-12-31 | 7.30 | INF% |
| 2003-12-31 | N/A | NAN% |
| 2002-12-31 | N/A |
P/B ratio for similar companies or competitors
| Company | P/B ratio | differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 5.43 | -79.53% | 🇺🇸 USA |
 Pfizer PFE | 2.31 | -91.29% | 🇺🇸 USA |
 Eli Lilly LLY | 37.5 | 41.26% | 🇺🇸 USA |
 Sanofi SNY | 1.61 | -93.91% | 🇫🇷 France |
 Baxter BAX | 3.59 | -86.48% | 🇺🇸 USA |
 MannKind Corp MNKD | -4.24 | -115.96% | 🇺🇸 USA |